In this task, you are given text for US Congressional and California state bills, your task is to generate a summary for this bill.
One example: SECTION 1. LIABILITY OF BUSINESS ENTITIES PROVIDING USE OF FACILITIES
TO NONPROFIT ORGANIZATIONS.

(a) Definitions.--In this section:
(1) Business entity.--The term ''business entity'' means a
firm, corporation, association, partnership, consortium, joint
venture, or other form of enterprise.
(2) Facility.--The term ''facility'' means any real
property, including any building, improvement, or appurtenance.
(3) Gross negligence.--The term ''gross negligence'' means
voluntary and conscious conduct by a person with knowledge (at
the time of the conduct) that the conduct is likely to be
harmful to the health or well-being of another person.
(4) Intentional misconduct.--The term ''intentional
misconduct'' means conduct by a person with knowledge (at the
time of the conduct) that the conduct is harmful to the health
or well-being of another person.
(5) Nonprofit organization.--The term ''nonprofit
organization'' means--
(A) any organization described in section 501(c)(3)
of the Internal Revenue Code of 1986 and exempt from
tax under section 501(a) of such Code; or
(B) any not-for-profit organization organized and
conducted for public benefit and operated primarily for
charitable, civic, educational, religious, welfare, or
health purposes.
(6) State.--The term ''State'' means each of the several
States, the District of Columbia, the Commonwealth of Puerto
Rico, the Virgin Islands, Guam, American Samoa, the Northern
Mariana Islands, any other territory or possession of the
United States, or any political subdivision of any such State,
territory, or possession.
(b) Limitation on Liability.--
(1) In general.--Subject to subsection (c), a business
entity shall not be subject to civil liability relating to any
injury or death occurring at a facility of the business entity
in connection with a use of such facility by a nonprofit
organization if--
(A) the use occurs outside of the scope of business
of the business entity;
(B) such injury or death occurs during a period
that such facility is used by the nonprofit
organization; and
(C) the business entity authorized the use of such
facility by the nonprofit organization.
(2) Application.--This subsection shall apply--
(A) with respect to civil liability under Federal
and State law; and
(B) regardless of whether a nonprofit organization
pays for the use of a facility.
(c) Exception for Liability.--Subsection (b) shall not apply to an
injury or death that results from an act or omission of a business
entity that constitutes gross negligence or intentional misconduct,
including any misconduct that--
(1) constitutes a crime of violence (as that term is
defined in section 16 of title 18, United States Code) or act
of international terrorism (as that term is defined in section
2331 of title 18) for which the defendant has been convicted in
any court;
(2) constitutes a hate crime (as that term is used in the
Hate Crime Statistics Act (28 U.S.C. 534 note));
(3) involves a sexual offense, as defined by applicable
State law, for which the defendant has been convicted in any
court; or
(4) involves misconduct for which the defendant has been
found to have violated a Federal or State civil rights law.
(d) Superseding Provision.--
(1) In general.--Subject to paragraph (2) and subsection
(e), this Act preempts the laws of any State to the extent that
such laws are inconsistent with this Act, except that this Act
shall not preempt any State law that provides additional
protection from liability for a business entity for an injury
or death with respect to which conditions under subparagraphs
(A) through (C) of subsection (b)(1) apply.
(2) Limitation.--Nothing in this Act shall be construed to
supersede any Federal or State health or safety law.
(e) Election of State Regarding Nonapplicability.--This Act shall
not apply to any civil action in a State court against a business
entity in which all parties are citizens of the State if such State
enacts a statute--
(1) citing the authority of this subsection;
(2) declaring the election of such State that this Act
shall not apply to such civil action in the State; and
(3) containing no other provision.
Solution is here: Shields a business entity from civil liability relating to any injury or death occurring at a facility of that entity in connection with a use of such facility by a nonprofit organization if: (1) the use occurs outside the scope of business of the business entity; (2) such injury or death occurs during a period that such facility is used by such organization; and (3) the business entity authorized the use of such facility by the organization.
Makes this Act inapplicable to an injury or death that results from an act or omission of a business entity that constitutes gross negligence or intentional misconduct, including misconduct that: (1) constitutes a hate crime or a crime of violence or act of international terrorism for which the defendant has been convicted in any court; or (2) involves a sexual offense for which the defendant has been convicted in any court or misconduct for which the defendant has been found to have violated a Federal or State civil rights law.
Preempts State laws to the extent that such laws are inconsistent with this Act, except State law that provides additional protection from liability. Specifies that this Act shall not be construed to supersede any Federal or State health or safety law.
Makes this Act inapplicable to any civil action in a State court against a business entity in which all parties are citizens of the State if such State, citing this Act's authority and containing no other provision, enacts a statute declaring the State's election that this Act shall not apply to such action in the State.
Explanation: This Bill focuses on shielding business entities from civil liability relating to an injury or death depending on the conditions of injury, hence the generated summary is correct.

Now, solve this: SECTION 1. SHORT TITLE.

This Act may be cited as the ''Dextromethorphan Abuse Reduction Act
of 2007''.

SEC. 2. FINDINGS.

Congress finds the following:
(1) When used properly, cough medicines that contain
dextromethorphan have a long history of being safe and
effective. But abuse of dextromethorphan at high doses can
produce hallucinations, rapid heart beat, high blood pressure,
loss of consciousness, and seizures. The dangers multiply when
dextromethorphan is abused with alcohol, prescription drugs, or
narcotics.
(2) Dextromethorphan is inexpensive, legal, and readily
accessible, which has contributed to the increased abuse of
that drug, particularly among teenagers.
(3) Increasing numbers of teens and others are abusing
dextromethorphan by ingesting it in excessive quantities.
Prolonged use at high doses can lead to psychological
dependence on the drug. Abuse of dextromethorphan can also
cause impaired judgment, which can lead to injury or death.
(4) Dextromethorphan abuse increased by a factor of 10
during the period of 1999 through 2004, with an increase by a
factor of 15 among children aged 9 to 17 years.
(5) An estimated 2,400,000 teenagers (1 in 10) abused over-
the-counter cough medicines in 2005. Children ages 9 to 17
years are the fastest growing group of dextromethorphan
abusers.
(6) The Food and Drug Administration has called the abuse
of dextromethorphan a ''serious issue'' and a ''disturbing new
trend'' that can cause ''death as well as other serious adverse
events such as brain damage, seizure, loss of consciousness,
and irregular heartbeat.''.
(7) In recognition of the problem, several retailers have
voluntarily implemented age restrictions on purchases of cough
and cold medicines containing dextromethorphan.
(8) Prevention is a key component of addressing the rise in
the abuse of legal medications. Education campaigns teaching
teens and parents about the dangers of these drugs are an
important part of this effort.

SEC. 3. DEXTROMETHORPHAN.

(a) Definitions.--Section 102 of the Controlled Substances Act (21
U.S.C. 802) is amended by adding at the end the following:
''(50) The term 'finished dosage form', relating to
dextromethorphan, means dextromethorphan that--
''(A) is--
''(i) in a tablet, capsule, solution, liquid, or
other form intended for retail sale, and that generally
contains inactive ingredients; and
''(ii) approved under the Federal Food, Drug, and
Cosmetic Act (21 U.S.C. 301 et seq.) as a
nonprescription drug (as that term is defined in
section 760 of that Act (21 U.S.C. 379aa)); or
''(B) has been combined with other active or inactive
ingredients during the process of manufacturing a tablet,
capsule, solution, liquid, or other form described in
subparagraph (A).
''(51) The term 'unfinished', relating to dextromethorphan, means
any concentration or amount of dextromethorphan that is not in finished
dosage form.''.
(b) Unfinished Dextromethorphan.--Schedule V of section 202(c) of
the Controlled Substances Act (21 U.S.C. 812(c)) is amended by adding
at the end the following:
''(6) Unfinished dextromethorphan.''.
(c) Sales of Dextromethorphan in Finished Dosage Form.--
(1) In general.--Part D of title II of the Controlled
Substances Act (21 U.S.C. 841 et seq.) is amended by adding at
the end the following:

''SEC. 424. CIVIL PENALTIES FOR CERTAIN DEXTROMETHORPHAN SALES.

''(a) In General.--
''(1) Sale.--
''(A) In general.--Except as provided in paragraph
(2), it shall be unlawful for any person to knowingly
sell, cause another to sell, or conspire to sell a
product containing dextromethorphan to an individual
under the age of 18 years, including any such sale
using the Internet.
''(B) Failure to check identification.--If a person
fails to request identification from an individual
under the age of 18 years and sells a product
containing dextromethorphan to that individual, that
person shall be deemed to have known that the
individual was under the age of 18 years.
''(C) Affirmative defense.--It shall be an
affirmative defense to an alleged violation of
subparagraph (A) that the person selling a product
containing dextromethorphan examined the purchaser's
identification card and, based on that examination,
that person reasonably concluded that the
identification was valid and indicated that the
purchaser was not less than 18 years of age.
''(2) Exception.--This section shall not apply to any sale
made pursuant to a validly issued prescription.
''(b) Fines.--
''(1) In general.--The Attorney General may impose a civil
penalty on a person for violating subsection (a)(1)(A),
including a violation of that subsection committed by an
employee or agent of such person.
''(2) Maximum amount.--A civil penalty imposed under
paragraph (1) shall be--
''(A) not more than $1,000 for the first violation
of subsection (a)(1)(A) by a person;
''(B) not more than $2,000 for the second violation
of subsection (a)(1)(A) by a person; and
''(C) not more than $5,000 for the third violation,
or a subsequent violation, of subsection (a)(1)(A) by a
person.
''(3) Number of violations.--If a person makes sales of
dextromethorphan at more than 1 location, for purposes of
determining the number of violations by that person under this
subsection each individual location operated by that person
shall be considered a separate person.
''(c) Definition of Identification Card.--In this section, the term
'identification card' means an identification card that--
''(1) includes a photograph and the date of birth of the
individual;
''(2) is issued by a State or the Federal Government; and
''(3) is considered acceptable for purposes of sections
274a.2(b)(1)(v)(A) and 274a.2(b)(1)(v)(B)(1) of title 8, Code
of Federal Regulations (as in effect on or after the date of
the enactment of the Dextromethorphan Abuse Reduction Act of
2007).''.
(2) Regulations.--
(A) Internet sales.--Not later than 180 days after
the date of enactment of this Act, the Attorney General
of the United States shall promulgate regulations for
Internet sales of products containing dextromethorphan
to ensure compliance with section 424 of the Controlled
Substances Act, as added by this Act.
(B) Civil penalties.--
(i) In general.--Not later than 180 days
after the date of enactment of this Act, the
Attorney General of the United States shall
promulgate regulations to carry out section 424
of the Controlled Substances Act, as added by
this Act.
(ii) Contents.--The regulations promulgated
under clause (i) shall--
(I) provide for a range of fines
for a retailer, based on whether the
retailer or an employee or agent of
that retailer has committed prior
violations of section 424(a) of the
Controlled Substances Act, as added by
this Act; and
(II) require consideration of
whether a fine to be imposed on a
retailer should be reduced or
eliminated based on--
(aa) the establishment and
administration of an effective
employee training program by a
retailer relating to this Act
and the amendments made by this
Act; or
(bb) other actions taken by
a retailer to ensure compliance
with this Act and the
amendments made by this Act.
(C) Definition of retailer.--In this paragraph, the
term ''retailer'' means a grocery store, general
merchandise store, drug store, convenience store, or
other entity or person whose activities as a
distributor relating to products containing
dextromethorphan are limited almost exclusively to
sales for personal use, both in number of sales and
volume of sales, either directly to walk-in customers
or in face-to-face transactions by direct sales.
(3) Sense of the senate.--It is the sense of the Senate
that--
(A) manufacturers of products containing
dextromethorphan should contain language on packages
cautioning consumers about the dangers of
dextromethorphan misuse; and
(B) retailers selling products containing
dextromethorphan should impose appropriate safeguards
to protect against the theft of such products.
(d) Prevention Funding.--
(1) The partnership for a drug-free america.--
(A) In general.--The Director of National Drug
Control Policy shall make a directed grant to the
Partnership for a Drug-Free America to provide
education to individuals under the age of 18 years and
parents regarding preventing the abuse of prescription
and nonprescription drugs (including dextromethorphan).
(B) Authorization of appropriations.--In addition
to any other amounts authorized to be appropriated,
there are authorized to be appropriated $4,000,000 for
each of fiscal years 2008 through 2010 to carry out
this paragraph.
(2) Community anti-drug coalition of america.--
(A) In general.--The Director of National Drug
Control Policy shall make a directed grant to the
Community Anti-Drug Coalition of America to provide
education, training, and technical assistance to
community coalitions regarding preventing the abuse of
prescription and nonprescription drugs (including
dextromethorphan).
(B) Authorization of appropriations.--There are
authorized to be appropriated $4,000,000 for each of
fiscal years 2008 through 2010 to carry out this
paragraph.
(3) Supplement not supplant.--Grant funds provided under
this subsection shall be used to supplement, not supplant,
Federal and non-Federal funds available for carrying out the
activities described in this subsection.
(e) Supplemental Grants for Communities With Major Prescription and
Nonprescription Drug Issues.--
(1) Definitions.--In this subsection--
(A) the term ''Administrator'' means the
Administrator of the Substance Abuse and Mental Health
Services Administration;
(B) the term ''drug'' has the meaning given that
term in section 201 of the Federal Food, Drug, and
Cosmetic Act (21 U.S.C. 321);
(C) the term ''eligible entity'' means an
organization that--
(i) on or before the date of submitting an
application for a grant under this subsection,
receives a grant under the Drug-Free
Communities Act of 1997 (21 U.S.C. 1521 et
seq.); and
(ii) has documented, using local data,
rates of prescription or nonprescription drug
abuse above national averages, as determined by
the Administrator (including appropriate
consideration of the Monitoring the Future
Survey by the University of Michigan), for
comparable time periods;
(D) the term ''nonprescription drug'' has the
meaning given that term in section 760 of the Federal
Food, Drug, and Cosmetic Act (21 U.S.C. 379aa); and
(E) the term ''prescription drug'' means a drug
described in section 503(b)(1) of the Federal Food,
Drug, and Cosmetic Act (21 U.S.C. 353(b)(1)).
(2) Authorization of program.--The Administrator, in
consultation with the Director of the Office of National Drug
Control Policy, may make enhancement grants to eligible
entities to implement comprehensive community-wide strategies
that address abuse of prescription and nonprescription drugs.
(3) Application.--
(A) In general.--An eligible entity desiring an
enhancement grant under this subsection shall submit an
application to the Administrator at such time, in such
manner, and accompanied by such information as the
Administrator may require.
(B) Criteria.--As part of an application for a
grant under this subsection, the Administrator shall
require an eligible entity to submit a detailed,
comprehensive, multisector plan for addressing abuse of
prescription and nonprescription drugs.
(4) Uses of funds.--An eligible entity that receives a
grant under this subsection shall use the grant funds for
implementing a comprehensive, community-wide strategy that
addresses abuse of prescription and nonprescription drugs
issues in that community, in accordance with the plan submitted
under paragraph (3)(B).
(5) Grant terms.--A grant under this subsection--
(A) shall be made for a period of not more than 4
years; and
(B) shall not be in an amount of more than $50,000
per year.
(6) Supplement not supplant.--Grant funds provided under
this subsection shall be used to supplement, not supplant,
Federal and non-Federal funds available for carrying out the
activities described in this subsection.
(7) Evaluation.--A grant under this subsection shall be
subject to the same evaluation requirements and procedures as
the evaluation requirements and procedures imposed on the
recipient of a grant under the Drug-Free Communities Act of
1997 (21 U.S.C. 1521 et seq.).
(8) Administrative expenses.--Not more than 6 percent of a
grant under this subsection may be expended for administrative
expenses.
(9) Authorization of appropriations.--There are authorized
to be appropriated $4,000,000 for each of fiscal years 2008
through 2010 to carry out this subsection.
(f) Data Collection.--It is the Sense of the Senate that Federal
agencies and grantees that collect data on drug use trends should
ensure that the survey instruments used by such agencies and grantees
include questions to ascertain changes in the trend of abuse of
prescription and nonprescription drugs.
(g) Technical and Conforming Amendments.--
(1) In general.--Section 201(g) of the Controlled
Substances Act (21 U.S.C. 811(g)) is amended--
(A) by striking paragraph (2); and
(B) by redesignating paragraph (3) as paragraph
(2).
(2) Table of contents.--The table of contents for the
Comprehensive Drug Abuse Prevention and Control Act of 1970
(Public Law 91-513; 84 Stat. 1236) is amended by inserting
after the item relating to section 423 the following:

''Sec. 424. Dextromethorphan sales.''.
Solution:
Dextromethorphan Abuse Reduction Act of 2007 - Amends the Controlled Substances Act to: (1) set forth definitions relating to dextromethorphan in unfinished or finished dosage form; (2) classify unfinished dextromethorphan as a Schedule V controlled substance; and (3) impose civil penalties for sales of products containing dextromethorphan to individuals under the age of 18.

Expresses the sense of the Senate that: (1) manufacturers of products containing dextromethorphan should provide warnings about the dangers of dextromethorphan misuse; and (2) retailers should impose safeguards to protect against the theft of products containing dextromethorphan.

Directs the Director of National Drug Control Policy to make grants to the Partnership for a Drug-Free America and the Community Anti-Drug Coalition of America for education programs to prevent the abuse of prescription and nonprescription drugs (including dextromethorphan).

Authorizes the Administrator of the Substance Abuse and Mental Health Services Administration to make grants to certain communities to implement comprehensive community-wide strategies for addressing abuse of prescription and nonprescription drugs.